Abstract BACKGROUND Minocycline blocks microglial TNF signaling and downstream NF-κB activation, which reduces the mesenchymal phenotype in preclinical models of GBM. Primary analysis D-TERMINED trial identified a maximal tolerated dose (MTD) oral minocycline at 150 mg BID combination with temozolomide radiation. In overall population, secondary objective improved PFS was not met. Here, respons...